IFITM proteins restrict antibody-dependent enhancement of dengue virus infection

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chan, Ying Kai ^a   Huang, I Chueh ^a   Farzan, Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON INDUCIBLE TRANSMEMBRANE 1 PROTEIN; INTERFERON INDUCIBLE TRANSMEMBRANE 2 PROTEIN; INTERFERON INDUCIBLE TRANSMEMBRANE 3 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; INTERFERON;

ANIMAL CELL; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFECTION CONTROL; LEUKEMIA CELL LINE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PATHOPHYSIOLOGY; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECONDARY INFECTION; VIRUS CELL INTERACTION; ANIMAL; CELL LINE; DENGUE VIRUS; IMMUNOLOGY; TUMOR CELL LINE; VIROLOGY;

DENGUE VIRUS; WEST NILE VIRUS;

ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; CELL LINE, TUMOR; DENGUE; DENGUE VIRUS; HUMANS; INTERFERONS; MEMBRANE PROTEINS; MICE;

EID: 84859132903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034508     Document Type: Article

References (27)

1. Gubler DJ, (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496.
2. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
3. Jessie K, Fong MY, Devi S, Lam SK, Wong KT, (2004) Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189: 1411-1418.
4. Halstead SB, (1970) Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42: 350-362.
5. Kliks SC, Nimmanitya S, Nisalak A, Burke DS, (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411-419.
6. Pierson TC, Diamond MS, (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.
7. Dowd KA, Pierson TC, (2011) Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411: 306-315.
8. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, et al. (2009) The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243-1254.
9. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, et al. (2011) Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7: e1001258.
10. Lu J, Pan Q, Rong L, He W, Liu SL, et al. (2011) The IFITM proteins inhibit HIV-1 infection. J Virol 85: 2126-2137.
11. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
12. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, et al. (2010) Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol 84: 8332-8341.
13. Lewin AR, Reid LE, McMahon M, Stark GR, Kerr IM, (1991) Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 199: 417-423.
14. Moffatt P, Gaumond MH, Salois P, Sellin K, Bessette MC, et al. (2008) Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res 23: 1497-1508.
15. Samuel CE, (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809, table of contents.
16. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR, (1984) Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38: 745-755.
17. Liu SY, Sanchez DJ, Cheng G, (2011) New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 23: 57-64.
18. Huang IC, Bosch BJ, Li F, Li W, Lee KH, et al. (2006) SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 281: 3198-3203.
19. Huang IC, Li W, Sui J, Marasco W, Choe H, et al. (2008) Influenza A virus neuraminidase limits viral superinfection. J Virol 82: 4834-4843.
20. Rodenhuis-Zybert IA, Wilschut J, Smit JM, (2011) Partial maturation: an immune-evasion strategy of dengue virus? Trends Microbiol 19: 248-254.
21. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E, (2000) Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 74: 7814-7823.
22. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718.
23. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823-829.
24. Moreno-Altamirano MM, Sanchez-Garcia FJ, Legorreta-Herrera M, Aguilar-Carmona I, (2007) Susceptibility of mouse macrophage J774 to dengue virus infection. Intervirology 50: 237-239.
25. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, et al. (2004) Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22: 3563-3574.
26. Littaua R, Kurane I, Ennis FA, (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183-3186.
27. Ubol S, Halstead SB, (2010) How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829-1835.